➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Colorcon
McKinsey
Express Scripts
McKesson

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

ZEMAIRA Drug Profile


Email this page to a colleague

« Back to Dashboard

UNDER DEVELOPMENT

When do Zemaira patents expire, and when can biosimilar versions of Zemaira launch?

Zemaira is a drug marketed by Csl Behring Llc and is included in one BLA.

The biologic ingredient in ZEMAIRA is .alpha.1-proteinase inhibitor human. A full profile is posted on the .alpha.1-proteinase inhibitor human profile page.

DrugPatentWatch® Biosimilar and Interchangeable Outlook for Zemaira

Indicators of Biosimilar Launch

Under Development

  Try it Free

Summary for Tradename: ZEMAIRA
Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for ZEMAIRA
Recent Clinical Trials for ZEMAIRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Michigan Cancer CenterPhase 2
The Leukemia and Lymphoma SocietyPhase 2
CSL BehringPhase 2

See all ZEMAIRA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZEMAIRA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZEMAIRA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZEMAIRA Derived from Patent Text Search

No patents found based on company disclosures

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKesson
Boehringer Ingelheim
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.